XML 80 R71.htm IDEA: XBRL DOCUMENT v3.23.2
Segment Information - Reportable Segment Information (Detail) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Net sales:        
Net sales $ 2,929 $ 3,307 $ 5,956 $ 6,533
Segment Adjusted Operating EBITDA:        
Adjusted Operating EBITDA 510 700 1,013 1,402
Other Depreciation and Amortization 287 301 563 604
Interest expense (116) (77) (227) (149)
Other income, net 21 (6) 15 10
Restructuring and other charges, net (7) (7) (59) (9)
Acquisition, divestiture, and integration related costs 45 61 76 110
Strategic initiative costs (9) 0 (22) 0
Regulatory costs (14) 0 (19) 0
Other gains (losses) 3 (2) (2) 5
Income before taxes 50 130 64 415
Business divestiture costs (20) (30) (41) (60)
Integration-related costs (20) (30) (30) (48)
Transaction related costs (5) (1) (5) (2)
Impairment of long-lived assets 0 (120) 0 (120)
Nourish        
Segment Adjusted Operating EBITDA:        
Restructuring and other charges, net (2) (1) (32) (3)
Health & Biosciences        
Segment Adjusted Operating EBITDA:        
Restructuring and other charges, net (1) (1) (11) (1)
Scent        
Segment Adjusted Operating EBITDA:        
Restructuring and other charges, net (4) (5) (14) (5)
Pharma Solutions        
Segment Adjusted Operating EBITDA:        
Restructuring and other charges, net 0 0 (2) 0
Corporate and Other        
Segment Adjusted Operating EBITDA:        
Restructuring and other charges, net (7) (7) (59) (9)
Operating Segments | Nourish        
Net sales:        
Net sales 1,564 1,818 3,217 3,549
Segment Adjusted Operating EBITDA:        
Segment Adjusted Operating EBITDA 181 365 389 694
Operating Segments | Health & Biosciences        
Net sales:        
Net sales 522 665 1,035 1,326
Segment Adjusted Operating EBITDA:        
Segment Adjusted Operating EBITDA 145 184 276 376
Operating Segments | Scent        
Net sales:        
Net sales 592 580 1,200 1,165
Segment Adjusted Operating EBITDA:        
Segment Adjusted Operating EBITDA 117 93 222 209
Operating Segments | Pharma Solutions        
Net sales:        
Net sales 251 244 504 493
Segment Adjusted Operating EBITDA:        
Segment Adjusted Operating EBITDA $ 67 $ 58 $ 126 $ 123